News

The signs were not in the headline growth rate but in which two products were trading places.

Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.

Pharmaceutical giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s favorite stocks in the sector. Over the course of this year, the CNBC TV host has praised the firm on multiple occasions. Among the reasons that he has been optimistic about Johnson & Johnson (NYSE:JNJ) include the firm’s cancer drug portfolio and its Triple […]

Icotyde expands the immunology portfolio while creating a simpler alternative to J&J's established Tremfya treatment.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

A $610,000 pension lump sum sounds like freedom, but the monthly check comes with a guarantee that a dividend portfolio simply cannot replicate. Before you sign anything, there are three numbers that expose which choice actually leaves you better off.

A seven-figure portfolio looks like security until federal taxes, Medicare surcharges, Social Security phase-ins, and inflation each take their share. What actually clears into your checking account from $1.55 million depends on decisions most retirees never see coming.

The U.S. FDA has expanded Johnson & Johnson (NYSE:JNJ) approval of Imaavy to treat warm autoimmune hemolytic anemia (wAIHA), a rare and potentially life-threatening blood disorder. The approval covers patients aged 12 and older who are currently receiving or have previously received steroids. This makes Imaavy the first approved treatment for this group of patients. […]

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]

Looking for a dividend stock you can sleep well owning? Here's why Johnson & Johnson could be the long-term healthcare anchor your portfolio needs.

Chasing a 7% blended yield across a $1.75 million portfolio sounds straightforward until you realize that loading up on the highest payers quietly destroys the very income stream you built. Three buckets solve the problem in ways that a single fund simply cannot.

The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.

U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

The company now leads with a cost-savings total and a growth rate that does not begin until the end of the decade, which tells a holder far less about whether its medicines are winning.

Johnson & Johnson (NYSE: JNJ) received FDA approval for IMAAVY (nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia (wAIHA). The approval introduces the first therapy specifically shown to be safe and effective for this rare and sometimes life-threatening blood disorder. IMAAVY is indicated to address an unmet patient need, with clinical data showing durable hemoglobin response and improved fatigue scores. The decision supports Johnson & Johnson’s rare disease...

The company's autoimmune drug was approved for the treatment of a rare blood disease.

Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial momentum across the company’s royalty streams and proprietary portfolio. For the first half of 2026, GMAB reported total revenue […]

JPMorgan, Johnson & Johnson and Mastercard headline today's research, with growth drivers and key risks shaping each stock's outlook.

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05% move from the preceding trading day.

For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

The company is firing on all cylinders.

While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That drug now represents a small fraction of the Innovative Medicine portfolio. The remaining 96% of that business is posting remarkable growth, expanding at over 14.

Imaavy opens an entirely new market, but one rare-disease indication cannot move Johnson & Johnson's valuation alone.

A nest egg of $840,000 sits right at the crossroads where dividends and annuities each look surprisingly compelling, and where the wrong choice quietly costs you tens of thousands of dollars over a 20-year retirement.